

Tilmann Bochtler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9174385/publications.pdf>

Version: 2024-02-01

40
papers

1,217
citations

430874

18
h-index

377865

34
g-index

41
all docs

41
docs citations

41
times ranked

1580
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 551-560.	2.8	4
2	Cryostorage to What End? â€œ Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 91-98.	1.6	1
3	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
4	Targeting rare and non-canonical driver variants in NSCLC â€œ An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	2.0	8
5	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. <i>European Journal of Cancer</i> , 2021, 157, 179-189.	2.8	13
6	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	5.2	102
7	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	5.1	14
8	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
9	Phase I doseâ€­escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	2.5	21
10	TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2619-2627.	7.2	19
11	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	3.7	32
12	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	3.5	29
13	Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?. <i>Frontiers in Oncology</i> , 2019, 9, 402.	2.8	38
14	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. <i>International Journal of Cancer</i> , 2019, 145, 2963-2973.	5.1	24
15	Micronucleus formation in human cancer cells is biased by chromosome size. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 392-395.	2.8	17
16	Diagnosis and management of metastatic neoplasms with unknown primary. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 199-206.	1.5	46
17	Enasidenib. <i>Recent Results in Cancer Research</i> , 2018, 212, 187-197.	1.8	4
18	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. <i>Blood</i> , 2018, 132, 1988-1991.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Hematological Malignancies in Adults With a Family Predisposition. <i>Deutsches Arzteblatt International</i> , 2018, 115, 848-854.	0.9	9
20	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1472-1472.	1.4	2
21	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1333-1342.	1.4	57
22	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 56-57.	3.0	9
23	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. <i>Haematologica</i> , 2017, 102, 1424-1431.	3.5	39
24	Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. <i>Haematologica</i> , 2017, 102, 1281-1290.	3.5	15
25	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. <i>Blood</i> , 2016, 128, 594-602.	1.4	67
26	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001123.	1.2	2
27	Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2869-2869.	1.4	0
28	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. <i>Journal of Clinical Oncology</i> , 2015, 33, 1371-1378.	1.6	185
29	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. <i>Blood</i> , 2015, 126, 1790-1790.	1.4	2
30	Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2008-2008.	1.4	0
31	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 9-17.	3.0	84
32	Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 3898-3905.	1.6	63
33	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. <i>Blood</i> , 2013, 122, 489-489.	1.4	1
34	Outcome Of Patients With Abn(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 303-303.	1.4	0
35	Efficacy Of Azacitidine Versus Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia - A Retrospective Single Center Experience. <i>Blood</i> , 2013, 122, 3974-3974.	1.4	0
36	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). <i>Blood</i> , 2013, 122, 1993-1993.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Treatment of AL Amyloidosis with Bendamustine. Blood, 2012, 120, 4057-4057.	1.4	5
38	Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood, 2011, 117, 3809-3815.	1.4	60
39	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica, 2008, 93, 459-462.	3.5	62
40	Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood, 2008, 111, 4700-4705.	1.4	103